Arcus Biosciences, Inc.
RCUS
$28.74
$0.020.07%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -74.38% | -39.29% | 26.92% | -45.83% | 310.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -74.38% | -39.29% | 26.92% | -45.83% | 310.26% |
| Cost of Revenue | -18.71% | 0.00% | 19.80% | 14.63% | 20.87% |
| Gross Profit | -442.86% | -11.70% | -17.33% | -53.33% | 127.63% |
| SG&A Expenses | -17.24% | 3.57% | -7.14% | -10.00% | -3.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.45% | 0.67% | 13.95% | 9.80% | 15.86% |
| Operating Income | -1,100.00% | -9.84% | -10.68% | -35.24% | 92.45% |
| Income Before Tax | -- | -14.29% | -13.98% | -46.74% | 100.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -14.29% | -12.77% | -46.74% | 100.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -14.29% | -12.77% | -46.74% | 100.00% |
| EBIT | -1,100.00% | -9.84% | -10.68% | -35.24% | 92.45% |
| EBITDA | -1,450.00% | -10.92% | -11.00% | -35.92% | 94.23% |
| EPS Basic | 36.60% | 10.32% | 12.74% | -25.93% | -11.49% |
| Normalized Basic EPS | -- | 10.32% | 11.80% | -25.94% | 100.00% |
| EPS Diluted | 36.60% | 10.32% | 12.74% | -25.93% | -11.49% |
| Normalized Diluted EPS | -- | 10.32% | 11.80% | -25.94% | 100.00% |
| Average Basic Shares Outstanding | 18.85% | 27.44% | 29.23% | 16.52% | 16.47% |
| Average Diluted Shares Outstanding | 18.40% | 27.44% | 29.23% | 16.52% | 16.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |